At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 51 enrolled
Drug / intervention
Qsymia +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects
In Brief
A Phase 4 clinical trial evaluating Qsymia and Placebo for Obesity. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedSep 2014
Primary CompletionNov 2014
TodayJul 2026
First PostedSep 1, 2014
Enrollment StartAug 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.8 years ago
Interventions
Qsymiadrug
Placebodrug